Comparison of behavioral effects of moclobemide and deprenyl during forced swimming

Pharmacology Biochemistry and Behavior

Volumn 60, Issue 2, 1998, Pages 431-437

  Ferigolo, Maristela ^a   Barros, Helena M T ^a   Marquardt, André R ^a   Tannhauser, Mario ^a  

^a Federal School of Medical Sciences of Porto Alegre   (Brazil)

Author keywords

Antidepressants; Forced swimming; MAO A inhibitor; MAO B inhibitor; Monoamine oxidase inhibitors; Phenylethylamine; Selegiline

Indexed keywords

IMIPRAMINE; MOCLOBEMIDE; PHENETHYLAMINE; SELEGILINE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CLIMBING; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; LOCOMOTION; NONHUMAN; PRIORITY JOURNAL; RAT; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BEHAVIOR, ANIMAL; BENZAMIDES; IMIPRAMINE; MALE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; PHENETHYLAMINES; PSYCHOTROPIC DRUGS; RATS; RATS, WISTAR; SELEGILINE; SWIMMING;

EID: 0032101019     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00011-2     Document Type: Article

References (37)

1. Amrein R., Hetzel W., Stabl M., Schmid-Burgk W. RIMA a safe concept in the treatment of depression with moclobemide. Can. J. Psychiatry. 37(Suppl. 1):1992;7-11.
2. Birkmayer W., Riederer P., Linauer W., Knoll J. L-Deprenyl plus l-phenylalanine in the treatment of depression. J. Neural Transm. 59:1984;81-87.
3. Burkard W.P., Bonetti E.P., Da Prada M., Martin J.R., Polc P., Schaffner R., Scherschlicht R., Hefti F., Müller R.K.M., Wyss P., Haefely W. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J. Pharmacol. Exp. Ther. 248:1989;391-399.
4. Callingham B.A. Drug interactions with reversible monoamine oxidase-A inhibitors. Clin. Neuropharmacol. 16(Suppl. 2):1993;42-50.
5. Cicardo V.H., Carbone S.E., de Rondina D.C., Mastronardi I.O. Stress by forced swimming in the rat. Effects of mianserin and moclobemide on gabaergic-monoaminergic systems in the brain Comp. Biochem. Physiol. 83:1986;133-135.
6. Da Prada M., Kettler R., Kelleer H.H., Burkard W.P., Muggli-Maniglio D., Haefely W.E. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J. Pharmacol. Exp. Ther. 248:1989;400-414.
7. Davis B.A., Boulton A.A. The trace amines and their acidic metabolites in depression-an overview. Prog. Neuropsychopharmacol. Biol. Psychiatry. 18:1994;17-45.
8. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berlin). 121:1995;66-72.
9. Fischer E., Spatz H., Heller B., Reggiani H. Phenylethylamine content of human urine and rat brain, its alteration in pathologic conditions and after drug administration. Experientia. 283:1972;307-308.
10. Glover V., Elsworth J.D., Sandler M. Dopamine oxidation and its inhibition by (-) deprenyl in man. J. Neural. Transmission. (Suppl.). 16:1980;163-172.
11. Heinonen E.H., Lammintausta R. A review of the pharmacology of selegiline. Acta Neurol. Scand. 136(Suppl. 84):1991;44-59.
12. Johnston J.P. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. 17:1968;1285-1297.
13. Knoll J. Deprenyl (Selegiline). The history of its development and pharmacological action Acta Neurol. Scand. (Suppl.). 95:1983;57-80.
14. Knoll J. The pharmacological profile of (-) deprenyl (selegeline) and its relevance for humans. A personal view Pharmacol. Toxicol. 70:1992;317-321.
15. Knoll J., Miklya I. Enhanced catecholaminergic and serotonergic activity in rat brain from weaning to sexual maturity. Rationale for prophylactic (-) deprenyl (selegeline) medication Life Sci. 56:1995;611-620.
16. Knoll J., Miklya I., Knoll B., Markó R., Kelemen K. -) Deprenyl and (-) l-phenyl-2-propylaminopentane, [(-) PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons. Life Sci. 58:1996;817-827.
17. Knoll J., Miklya I., Knoll B., Markó R., Ráez D. Phenylethylamine and tyramine are mixed-action sympathomimetic amines in the brain. Life Sci. 58:1996;817-827.
18. Larsen J.K., Gjerries A., Holman P., Andersen J., Bille A., Christensen E.M., Hoyer E., Jensen H., MejHede A., Langargergaard A., Laursen A.L., Nilakantan B., Olafssonn K., Severin B., Rafaelsen O.J. Moclobemide in depression. A randomized, multicentric trial against isocarboxazide and clomipramine emphasizing atypical depression Acta Psychiatr. Scand. 84:1991;564-570.
19. Mann J., Gershon S. L-Deprenyl a selective monoamine oxidase type-B inhibitor in endogenous depression. Life Sci. 26:1980;877-882.
20. Mendis N., Pare C.M.B., Sandler M., Glover V., Stern G.M. Is the failure of (-) deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect. Psychopharmacology (Berlin). 73:1981;87-90.
21. Mendlewicz J., Youdim B.H. L-Deprenyl, a selective monoamine oxidase type B inhibitor, in the treatment of depression. A double blind evaluation Br. J. Psychiatry. 142:1983;508-511.
22. Miura H., Naoi M., Nakahara D., Ohta T., Nagatsu T. Effects of moclobemide on force-swimming stress and brain monoamine levels in mice. Pharmacol. Biochem. Behav. 53:1996;469-475.
23. Murphy D.L. Substrate-selective monoamine oxidases-inhibitor, tissue, species and functional differences. Biochem. Pharmacol. 27:1978;1889-1893.
24. Nakagawara M. B-phenylethylamine and noradrenergic function in depression. Prog. Neuropsychopharmacol. Biol Psychiatry. 16:1992;45-53.
25. O'Reilly R.L., Davis B.A. Phenylethylamine and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 18:1994;63-75.
26. Paterson I.A., Juorio A.V., Boulton A.A. 2-Phenylethylamine. A modulator of catecholamine transmission in the mammalian central nervous system? J. Neurochem. 55:1990;1827-1837.
27. Porsolt D.R., Le Pichon M., Jalfre M. Depression. A new animal model sensitive to antidepressant treatments Nature. 266:1977;730-732.
28. Porsolt D.R., Jalfre M. Swimming rats and human depression. Nature. 274:1978;512-513.
29. Porsolt D.R., Anton G., Blavet N., Jalfre M. Behavioral despair in rats. A new model sensitive to antidepressant treatments Eur. J. Pharmacol. 47:1978;379-391.
30. Reynolds G.P., Elsworth J.D., Blau K., Sandler M., Lees M.J., Stern G.M. Deprenyl is metabilized to methamphetamine and amphetamine in man. Br. J. Clin. Pharmacol. 6:1978;542-544.
31. Sabelli H.C., Mosnaim A.D. Phenylethylamine hypotesis of affective behavior. Am. J. Psychiatry. 131:1974;695-699.
32. Schoerlin M.P., Da Prada M. Species-species biotransformation of moclobemide. A comparative study in rats and humans Acta Psychiatr. Scand. 360:1990;108-110.
33. Versiani M., Oggero U., Alterwain P., Capponi R., Dajas F. A double-blind comparative trial of moclobemide vs. imipramine and placebo in major depressive episodes. Br. J. Psychiatry. 155(Suppl. 6):1989;72.
34. Wieland S., Fischette C.T., Lucki I. Effect of chronic treatments with tandospirone and imipramine on serotonin-mediated behavioral responses and monoamine receptors. Neuropharmacology. 32:1993;561-573.
35. Willner P. The validity of animal models of depression. Psychopharmacology (Berlin). 83:1984;1-16.
36. Yang H.Y.T., Neff N.H. B-phenylethylamine. A specific substrate for type B monoamine oxidase of brain J. Pharmacol. Exp. Ther. 187:1973;365-371.
37. Yu P.H. Pharmacological and clinical implications of MAO-B inhibitors. Gen. Pharmacol. 25:1994;1527-1539.